case-reports-2018-keynote

2 / 6

Medical Case Reports
ISSN: 2471-8041
May 28-29, 2018
London, UK
Case Reports 2018
Page 16
8th Edition of International Conference on
Clinical and Medical Case Reports
Background: Mammary analog secretory carcinoma (MASC)
was first described in 2010 as a rare salivary glands malignancy
characterized by similarities to breast secretory carcinoma (BSC)
in histology, immunohistochemistry and genetics. It accounts for
less than 1% of salivary tumors, with a mean age of 46 years.
The majority cases occur in the parotid gland, and the mean
size of the tumors is 2.1 cm, with almost no gender predilection.
Morphologically, it usually is a low grade malignancy, with low-
grade nuclei and moderate eosinophilic granular cytoplasm.
Differential Diagnosis: Immunohistochemistry shows MASC
to be positive for cytokeratins AE1/3, CK7, CK8, CK18,
Mammaglobin, S100, Vimentin and STAT5a, but negative for
Dog1, ER, PR and Her-2. GCDFP-15, p63, SMA and Calponin
are also positive in some MASC tumors. The major differential
diagnoses of MASC are acinic cell carcinomas, mucoepidermoid
carcinomas, adenocarcinomas not otherwise specified (NOS)
and cystadenocarcinomas.
Molecular Testing: FISH analysis ETV6-NTRK3 fusion gene
t(12;15)(p13;q25) product is a constitutively active chimeric
tyrosine kinase and has the transformation capacity in the
mammary epithelial andmyoepithelial cells. It has been reported
that the ETV6-NTRK3 fusion is unique to MASC.
Molecular Treatment: The prognosis of low grade MASC is
very good, although local recurrence may occur, and rarely
there is distant metastasis. Recent studies of targeting receptor
Kinases-2 on Entrectinib clinical trial STARTRK-2 show patients
with NTRK1/2/3 gene rearrangements may potentially benefit
from treatment with Entrectinib. Entrectinib (formerly RXDX-101)
is a potent inhibitor of kinases encoded by the gene NTRK3 of
MASC.
Biography
Dr. Beverly Wang is a professor of UC School of Medicine at Irvine. She
received her training at Mount Sinai Medical Center, also completied cyto-
pathology fellowship. She is a general surgical pathologist, specializing in
head and neck. She is vice chair of pathology and laboratory medicine and
chief of anatomic pathology, overseeing anatomic pathology services. Her
clinical interests include translational research, correlating head and neck
diseases, and tumors. Dr. Wang has published extensively. She has been
awarded a number of prestigious honors and has consistently been named
one of “America’s Top Doctors.”.
Update molecular diagnosis and treatment
on salivary gland tumors – Mammary Analog
Secretory Carcinoma
Beverly Wang
UC Irvine School of Medicine, USA
Beverly Wang, Med Case Rep. 2018, Volume 4
DOI:10.21767/2471-8041-C1-001